AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on…
Pharmaceuticals, Biotechnology and Life Sciences
Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on…
DUBLIN–(BUSINESS WIRE)–The “Global Ophthalmics Partnering 2014-2019: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering. Global Ophthalmics…
Data from a Phase 2 study in congenital hyperinsulinism (CHI) shared at ENDO 2019 and a budget impact model presented…
SAN DIEGO–(BUSINESS WIRE)–Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance,…
DUBLIN–(BUSINESS WIRE)–The “Global Sensory Organ Partnering 2014-2019: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering. Global…
DUBLIN–(BUSINESS WIRE)–The “Global Genetic disorders Partnering 2014-2019: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering. Global…
VIENNA, Va.–(BUSINESS WIRE)–The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc., a privately held, clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to…
Currently in a Phase 3 Pivotal Study for High-Risk Locally Advanced Cervical Cancer PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ: ADXS) (the Company),…
— Financing to Advance Lead Anti-CD47 Antibody AO-176 in Ongoing Phase 1 Clinical Trial and Pipeline — BRISBANE, Calif. and…